血液系统疾病并发院内感染的治疗  

Antimicrobial Therapy of Nosocomial Infectious Complications in Patients with Hematological Diseases

作　　者：黄洪晖[1] 陈芳源[1] 方智雯[1] 韩洁英[1] 朱学宏[1] 邵念贤[1] 

机构地区：[1]上海第二医科大学仁济医院血液科,上海200001

出　　处：《上海第二医科大学学报》2001年第2期177-179,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：目的观察亚胺培南 /西司他丁对血液系统疾病并发院内感染的治疗效果。　方法 5 2例患者 ,单一使用亚胺培南 /西司他丁或亚胺培南 /西司他丁与其他抗菌素合用。亚胺培南 /西司他丁每日剂量 1.5～ 2g ,静脉滴注。　结果 1 亚胺培南 /西司他丁治疗的总有效率为 5 9.6% ;2 对G+需氧菌及G-需氧菌感染的临床有效率分别为 4 4 .4 % ,60 .0 % ;3 应用第三代头孢菌素无效的患者用亚胺培南 /西司他丁治疗 ,总有效率达 5 6.4 % ;4 粒细胞缺乏合并感染患者中的有效率为 5 1.9%。　结论亚胺培南 /西司他丁具有高效、广谱的抗菌作用 ,是治疗血液系统疾病院内感染的有效药物。Objective To evaluate the clinical efficacy of imipenem/cilastatin in the treatment of nosocomial infectious complications in patients with hematological diseases. 52 patients were treated with imipenem/cilastatin alone or in combination with other antibiotics. It was administered intravenously at a dosage of 1.5 ～ 2g per day. 1. The overall response rate of imipe nem/cilastatin was 59.6%. 2. For Grme-positive and Grme-negative aerobes infections the clinical response rates were 44.4% and 60.0%, respectively. 3. The response rate of imipenem/cilastatin in patients who failed to respond to the third generation cephalosporins was 56.4%. 4. The response rate in febrile agranulocytosis patients was 51.9%. Imipenem/cilastatin is a highly effective and broad-spectrum antibacterial agent for the treatment of nosocomial infectious complications in patients with hematologic diseases.

关 键 词：亚胺培南 西司他丁 血液系统疾病 院内感染 并发症 治疗 急性白血病 骨髓增生异常综合征 

分 类 号：R733[医药卫生—肿瘤]